tldrdailynews.com logo
Tag

Lly

All articles tagged with #lly

Lilly’s Foundayo Launch Triggers Fresh Buy rating Amid Strong Demand Forecasts
markets1 month ago

Lilly’s Foundayo Launch Triggers Fresh Buy rating Amid Strong Demand Forecasts

BMO Capital Markets reiterates a Buy-equivalent rating on Eli Lilly (LLY) with a $1,300 target as the obesity pill Foundayo rolls out. Lilly expects $1.5–$2.8 billion in U.S. sales this year and up to $36 billion in peak annual sales globally, with Foundayo distributed through Weight Watchers (WW) and Amazon among other channels. The FDA approved Foundayo on April 1, and Wall Street remains bullish, with a consensus Strong Buy from 19 analysts and an average target around $1,247, implying roughly 31% upside from current levels.

via TipRanks|
#amzn#bmo#foundayo
HSBC Downgrades Lilly as Obesity Market Faces Pricing Pressures
market-news2 months ago

HSBC Downgrades Lilly as Obesity Market Faces Pricing Pressures

HSBC analyst Rajesh Kumar downgraded Eli Lilly (LLY) from Hold to Sell, arguing that pricing dynamics and a downsized total addressable market, intensified competition from Novo Nordisk, and potential headwinds for Lilly’s oral obesity drug orforglipron could limit upside; he cut the price target from $1,070 to $850 as TAM is viewed at about $80–120B versus consensus around $150B+, while the broader market remains bullish with a Strong Buy consensus and ~36% upside over the next year.

via TipRanks|
#healthcare#lly#market-news
"Viking Therapeutics Leads Weight-Loss Drug Fervor with Stock Surge"
finance2 years ago

"Viking Therapeutics Leads Weight-Loss Drug Fervor with Stock Surge"

Eli Lilly's stock is on the rise as it forms a flat base amidst increasing competition in the weight-loss drug space, particularly with Viking Therapeutics' promising test results for its experimental pill. Despite this, analysts remain optimistic about Lilly's weight-loss drugs, Zepbound and Wegovy, with expectations of significant sales growth. The company is also developing new pills targeting GLP-1 and GIP, aiming for stronger weight loss. Eli Lilly stock has shown strength in technical and fundamental measures, remaining above its 50-day moving average and boasting a strong Relative Strength Rating and Composite Rating.

via Investor's Business Daily|
#eli-lilly#finance#lly